The Gut-Heart Axis in Dogs: Nutritional Strategies for Cardiovascular Health

How Gut Health Shapes Cardiac Function, Metabolite Production, and Long-Term Cardiovascular Wellbeing

“The gut-heart axis reveals a critical connection between intestinal health and cardiovascular function. While heart disease affects 10-15% of dogs, we can profoundly influence the gut-derived metabolites and inflammatory pathways that determine cardiac health and longevity.”

Summary

Dogs with heart disease consistently show gut dysbiosis. Research confirms that the gut-derived metabolite TMAO is elevated in both preclinical and advanced myxomatous mitral valve disease, and that gut microbiome composition directly influences cardiac inflammation, blood vessel function, and cardiovascular disease progression. This relationship means that the trillions of microorganisms residing in your dog’s gut directly affect their cardiac function, blood vessel health, and risk of cardiovascular disease through metabolite production, immune signalling, and inflammatory pathways. Research demonstrates that dogs with heart disease, including the prevalent myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM), consistently show gut dysbiosis with altered microbiome compositions compared to healthy dogs.^1,2 This comprehensive guide explores the science underlying gut-heart communication, examines its implications for common canine cardiac conditions, and provides evidence-based nutritional strategies for supporting your dog’s cardiovascular health through targeted gut optimisation.

At Bonza, the gut-heart axis is one of the eight gut-organ axes central to the “One Gut. Whole Dog.” philosophy, with the Biotics Triad in Bioactive Bites supporting the gut microbiome environment in which cardioprotective SCFAs are produced and TMAO precursor metabolism is modulated, alongside the plant-based profile of Superfoods & Ancient Grains, which naturally reduces the dietary choline and betaine load associated with elevated TMAO.

Key Takeaways

• The gut-heart axis describes bidirectional communication between the gastrointestinal tract and cardiovascular system, operating through gut-derived metabolites, immune signalling, and inflammatory pathways that directly influence cardiac health and function.^10,12
• Trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, has emerged as a significant marker in canine heart disease, dogs with both preclinical MMVD and congestive heart failure show elevated TMAO levels compared to healthy controls.^5,11
• Short-chain fatty acids (SCFAs) produced by beneficial gut bacteria have cardioprotective effects, reducing systemic inflammation, supporting blood vessel function, and helping regulate blood pressure.^10,12
• Dogs with congestive heart failure demonstrate gut dysbiosis characterised by increased Proteobacteria (particularly E. coli) and reduced beneficial bacteria, mirroring patterns observed in human heart failure patients.¹
• Increased intestinal permeability (‘leaky gut’) allows bacterial endotoxins like lipopolysaccharide (LPS) to enter circulation, triggering chronic inflammation that contributes to cardiac dysfunction and disease progression.^10,16
• Taurine deficiency linked to certain diets can cause a reversible form of dilated cardiomyopathy, highlighting the profound impact of nutrition on heart health through gut-mediated pathways.^6,7
• Omega-3 fatty acids (EPA and DHA) provide multiple cardiovascular benefits including anti-arrhythmic effects, reduced inflammation, improved endothelial function, and support for healthy blood pressure.^8,14,15
• Plant-based diets may help reduce circulating levels of TMAO precursors (choline and betaine), potentially offering cardiovascular protective benefits through modification of gut microbiome metabolite production.⁴
• A comprehensive nutritional approach combining gut health support with cardiac-supporting nutrients offers the most effective strategy for optimising cardiovascular function and supporting dogs with heart conditions.¹⁶

Table of Contents

Introduction: The Heart-Gut Connection

Understanding the Gut-Heart Axis

• The Microbiome’s Role in Cardiovascular Health
• Communication Pathways Between Gut and Heart
• Trimethylamine N-Oxide (TMAO): A Critical Metabolite
• Short-Chain Fatty Acids and Cardiovascular Protection
• Intestinal Permeability and Cardiac Inflammation

Myxomatous Mitral Valve Disease and the Gut-Heart Connection

Dilated Cardiomyopathy: Nutritional Factors and Gut Health

Congestive Heart Failure and Gut Dysfunction

Hypertension and the Gut Microbiome

Nutritional Modulation of the Gut-Heart Axis

• Prebiotics for Cardiovascular Health
• Probiotics and Postbiotics
• Omega-3 Fatty Acids
• Taurine and L-Carnitine
• Coenzyme Q10
• Anti-Inflammatory Botanicals
• Antioxidants for Cardiac Protection

Dietary Strategies for Cardiovascular Health

Practical Implementation for Dog Owners

Supporting Your Dog’s Gut-Heart Axis: The Bonza Approach

Frequently Asked Questions

Conclusion

References

Introduction: The Heart-Gut Connection

Cardiovascular disease remains one of the leading causes of morbidity and mortality in dogs, with an estimated 10-15% of all dogs affected by some form of heart condition. When we think about canine heart health, the focus naturally turns to the heart itself, its valves, muscle, and rhythm. Yet emerging research reveals that cardiovascular health is intimately connected to a seemingly unrelated organ system: the gut. The gut-heart axis describes the complex bidirectional communication between the gastrointestinal tract and cardiovascular system, offering new understanding of why heart problems develop and how they might be prevented or managed through nutritional intervention.^10,12

The connection between gut and heart health is not coincidental, it reflects fundamental biology. The gut houses approximately 70-80% of the body’s immune tissue, and this immune hub influences inflammatory status throughout the body, including in cardiac tissues. More directly, gut bacteria produce metabolites that enter circulation and directly affect heart function, blood vessel health, and cardiovascular disease risk. Key among these metabolites are trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and bile acids, compounds that research has linked to cardiovascular outcomes in both dogs and humans.^11,12

For dogs with heart disease, whether myxomatous mitral valve disease (MMVD), the most common cardiac condition in dogs, or dilated cardiomyopathy (DCM), understanding the gut-heart axis opens powerful new therapeutic avenues. Research consistently demonstrates that dogs with heart failure show altered gut microbiome compositions compared to healthy dogs, with patterns remarkably similar to those observed in human heart failure patients.^1,2 This suggests that supporting gut health may complement conventional cardiac management, potentially improving outcomes and quality of life.

This article explores the intricate science behind the gut-heart axis in dogs, examining how the gut microbiome, intestinal barrier function, and circulating metabolites influence cardiovascular health. Most importantly, it provides practical guidance on using nutrition and targeted supplementation to optimise this vital connection, offering evidence-based strategies for supporting dogs at every stage of cardiac health, from proactive prevention to management of established heart disease.

Understanding the Gut-Heart Axis

The gut-heart axis encompasses the bidirectional communication network between the gastrointestinal system and the cardiovascular system. This relationship operates through multiple pathways including metabolite production, immune signalling, and inflammatory influences.¹⁰ Understanding these mechanisms reveals why gut health is inseparable from heart health and why nutritional strategies must address both systems simultaneously for optimal cardiovascular support.

The Microbiome’s Role in Cardiovascular Health

The gut microbiome, the vast community of bacteria, fungi, and other microorganisms inhabiting the gastrointestinal tract, profoundly influences cardiovascular function. A healthy, balanced microbiome promotes anti-inflammatory signalling and produces beneficial metabolites that support heart and blood vessel health. Conversely, dysbiosis, an imbalance favouring potentially harmful species over beneficial ones, promotes chronic low-grade inflammation and generates metabolites that can damage cardiovascular tissues.¹²

Research in dogs with heart disease has revealed consistent patterns of gut dysbiosis. A landmark pilot study examining dogs with congestive heart failure found significant microbiome alterations compared to healthy controls. The most pronounced finding was an increase in Proteobacteria, particularly Escherichia coli and Enterobacteriaceae.¹ Strikingly, these patterns mirror findings in human heart failure patients, suggesting conserved gut-heart axis mechanisms across species and validating dogs as a clinically relevant model for studying this connection.

The microbiome’s influence on cardiovascular health extends beyond simple bacterial populations. These organisms function as a metabolic organ, processing dietary components and producing bioactive compounds that circulate throughout the body. Beneficial bacteria produce cardioprotective short-chain fatty acids, while dysbiosis can lead to increased production of harmful metabolites like TMAO that promote cardiovascular disease.^10,11

Communication Pathways Between Gut and Heart

The gut and heart communicate through several interconnected pathways, each offering potential intervention points for nutritional support:

Metabolite signalling: Gut bacteria metabolise dietary components to produce compounds that enter systemic circulation and directly affect cardiac tissues. These include TMAO from choline and carnitine metabolism, SCFAs from fibre fermentation, and secondary bile acids from primary bile acid transformation.^11,13

Immune modulation: The gut-associated lymphoid tissue (GALT) represents the body’s largest immune organ. Gut bacteria influence immune cell development and function, shaping systemic inflammatory tone that affects cardiac tissue health and repair processes.¹²

Endotoxin translocation: When intestinal barrier function is compromised (‘leaky gut’), bacterial components like lipopolysaccharide (LPS) can enter circulation, triggering inflammatory cascades that promote endothelial dysfunction, atherosclerosis, and cardiac remodelling.^10,16

Autonomic nervous system: The enteric nervous system (‘second brain’) communicates with the cardiovascular system through vagal pathways. Gut inflammation can affect autonomic tone, potentially influencing heart rate variability and cardiac rhythm.

Trimethylamine N-Oxide (TMAO): A Critical Metabolite

Perhaps no gut-derived metabolite has received more attention in cardiovascular research than trimethylamine N-oxide (TMAO). This compound is produced when gut bacteria metabolise dietary precursors found abundantly in animal-based foods like meat, eggs, and fish.¹¹’¹³ The primary precursors are choline, phosphatidylcholine (lecithin), and L-carnitine.

The TMAO pathway works as follows: gut bacteria possessing the choline TMA-lyase enzyme convert dietary choline and carnitine into trimethylamine (TMA). TMA is then absorbed into circulation and transported to the liver, where hepatic flavin monooxygenases (FMO3) oxidise it to TMAO. Circulating TMAO then exerts effects throughout the cardiovascular system.¹¹

Research has demonstrated elevated TMAO levels in dogs with heart disease. A pilot study found that dogs with degenerative mitral valve disease and congestive heart failure had significantly higher plasma TMAO concentrations than healthy controls.⁵ Additionally, studies on dogs with MMVD have shown that TMAO and related metabolites are altered from the B2 disease stage onward, suggesting TMAO may serve as a biomarker for disease progression.^2,3

TMAO contributes to cardiovascular disease through multiple mechanisms:

• Promoting atherosclerosis by enhancing cholesterol accumulation in macrophages and foam cell formation
• Increasing platelet reactivity and thrombosis risk
• Promoting endothelial dysfunction through oxidative stress
• Contributing to cardiac fibrosis and adverse remodelling
• Enhancing inflammatory signalling in vascular tissues^11,12

Importantly, TMAO production is modifiable through diet. A pilot study in healthy dogs found that feeding a commercial extruded plant-based diet significantly lowered circulating levels of TMAO precursors (choline and betaine) compared to animal-based diets.⁴ This suggests that dietary composition can influence this cardiovascular risk pathway, offering a practical intervention strategy.

Short-Chain Fatty Acids and Cardiovascular Protection

While TMAO represents the ‘dark side’ of gut-derived metabolites, short-chain fatty acids (SCFAs) exemplify the cardioprotective potential of a healthy microbiome. SCFAs are produced when beneficial gut bacteria ferment dietary fibres and resistant starches.¹⁰ The primary SCFAs are acetate, propionate, and butyrate.

These metabolites exert cardiovascular benefits through multiple mechanisms:

Anti-inflammatory effects: SCFAs, particularly butyrate, suppress pro-inflammatory cytokine production and promote regulatory T-cell development, reducing the chronic inflammation that drives cardiovascular disease progression.¹²

Blood pressure regulation: SCFAs interact with G-protein coupled receptors (GPR41 and GPR43) in blood vessels and kidneys, influencing vascular tone and renin release. Studies suggest SCFAs generally promote vasodilation and healthy blood pressure.¹⁰

Gut barrier support: Butyrate serves as the primary energy source for colonocytes (intestinal lining cells), supporting tight junction integrity and preventing the endotoxin translocation that triggers systemic inflammation.^10,16

Metabolic regulation: SCFAs influence glucose and lipid metabolism, helping maintain healthy metabolic profiles that support cardiovascular function.

The balance between harmful metabolites like TMAO and beneficial SCFAs largely depends on microbiome composition and substrate availability. A diet rich in fermentable fibres feeds SCFA-producing bacteria, while excessive animal protein provides substrates for TMAO production. This balance offers a key leverage point for nutritional intervention.

Intestinal Permeability and Cardiac Inflammation

Intestinal barrier integrity, the ability of the gut lining to selectively allow nutrient absorption while excluding harmful substances, is increasingly recognised as central to the gut-heart axis. When this barrier is compromised, a condition often termed ‘leaky gut,’ bacterial components and metabolites that should remain in the intestinal lumen can enter systemic circulation.^10,16

Of particular concern is lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls. When LPS enters circulation (a process called endotoxaemia), it binds to toll-like receptor 4 (TLR4) on immune and vascular cells, triggering potent inflammatory responses. This ‘metabolic endotoxaemia’ promotes:

• Endothelial dysfunction and reduced nitric oxide availability
• Pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α)
• Oxidative stress and lipid peroxidation
• Cardiac fibrosis and adverse remodelling
• Progression of atherosclerosis¹⁰

Research in human heart failure patients has demonstrated elevated circulating LPS levels compared to healthy individuals, with levels correlating with disease severity. Similar mechanisms appear operative in dogs, where intestinal congestion secondary to heart failure may further compromise barrier function, creating a vicious cycle of gut dysfunction and cardiac deterioration.^1,10

Myxomatous Mitral Valve Disease and the Gut-Heart Connection

Myxomatous mitral valve disease (MMVD) is the most common cardiac condition in dogs, affecting up to 75% of small breed dogs over 16 years of age. In this degenerative condition, the mitral valve leaflets progressively thicken and deform, leading to valve regurgitation (backflow of blood), volume overload of the left atrium and ventricle, and ultimately heart failure in severely affected dogs.

Recent research has revealed intriguing connections between gut health and MMVD progression. A comprehensive study examining dogs at various MMVD stages found that gut dysbiosis and metabolic changes emerged from the B2 stage onward, before overt clinical heart failure develops.^2,3 This suggests that gut-heart axis alterations may contribute to disease progression, not merely result from it.

Key findings from MMVD gut-heart research include:

Altered microbiome composition: Dogs with MMVD show changes in bacterial community structure that worsen with disease stage. These alterations affect the functional capacity of the microbiome, influencing metabolite production.²

Metabolite changes: Beyond TMAO elevations, dogs with MMVD demonstrate alterations in amino acid metabolism, lipid profiles, and energy metabolites. These metabolomic signatures suggest widespread metabolic reprogramming associated with disease.³

TMAO correlations: Plasma TMAO levels in dogs with MMVD correlate with disease severity. Dogs with congestive heart failure secondary to MMVD show higher TMAO than those with preclinical disease, supporting TMAO as both a marker and potential contributor to progression.⁵

These findings have significant implications for nutritional management. Supporting gut health and optimising the gut-heart axis may help slow MMVD progression, particularly when implemented early in the disease course. The preclinical stages (B1 and B2) represent windows of opportunity where nutritional intervention may have the greatest impact before heart failure develops.

Dilated Cardiomyopathy: Nutritional Factors and Gut Health

Dilated cardiomyopathy (DCM) represents a different cardiac challenge, a disease of the heart muscle itself characterised by chamber dilation and impaired contractility. While genetic factors underlie most cases in predisposed breeds like Doberman Pinschers, Boxers, and Great Danes, nutritional forms of DCM have highlighted the profound connection between diet, gut health, and cardiac function.

The taurine-DCM connection provides a compelling illustration of gut-heart axis relevance. Taurine is an amino acid essential for cardiac muscle function, and its availability depends partly on dietary intake and partly on synthesis from methionine and cysteine. Certain dietary patterns can lead to taurine deficiency and subsequent DCM:

Diet-Associated DCM: Beginning in 2018, reports emerged of atypical DCM in breeds not typically predisposed, often associated with grain-free diets high in legumes and potatoes.⁷ Subsequent research revealed that many affected dogs had low taurine levels despite diets meeting minimum requirements.

Golden Retriever Study: A landmark study of 24 Golden Retrievers with taurine-deficient DCM found that 23 showed improvement when switched to taurine-supplemented conventional diets, with many showing complete echocardiographic normalisation.⁶ This remarkable reversibility underscores the potential for nutritional intervention.

American Cocker Spaniel Research: The multicenter spaniel trial (MUST) demonstrated that American Cocker Spaniels with DCM and low plasma taurine showed significant improvement with taurine and carnitine supplementation, establishing nutritional DCM as a distinct and treatable entity.⁹

The gut microbiome may influence taurine status through several mechanisms. Certain bacteria can metabolise taurine, potentially reducing its availability. Gut health also affects the absorption of taurine precursors and the enterohepatic circulation of bile acids (which are conjugated to taurine). This connection suggests that supporting gut health alongside taurine supplementation may optimise cardiac outcomes in at-risk dogs.¹⁷

Congestive Heart Failure and Gut Dysfunction

Congestive heart failure (CHF) represents the end stage of various cardiac diseases, including both MMVD and DCM. In CHF, the failing heart cannot maintain adequate circulation, leading to fluid accumulation, organ dysfunction, and characteristic clinical signs like coughing, breathing difficulty, and exercise intolerance.

The gut-heart connection in CHF creates a particularly challenging scenario. The ‘gut hypothesis of heart failure’ proposes that intestinal dysfunction both results from and contributes to cardiac deterioration, creating a vicious cycle:¹⁰

Intestinal congestion: Right-sided heart failure causes venous congestion affecting the intestines. This gut congestion impairs barrier function, promotes bacterial overgrowth, and alters microbiome composition.

Reduced cardiac output: Inadequate intestinal blood flow compromises oxygen and nutrient delivery to enterocytes, further weakening barrier integrity and reducing absorptive capacity.

Microbiome alterations: The pilot study in dogs with CHF found striking microbiome changes, with increased Proteobacteria (particularly E. coli and Enterobacteriaceae) and reduced beneficial populations.¹ These changes promote inflammation and harmful metabolite production.

Increased permeability: Compromised barrier function allows bacterial translocation and endotoxaemia, fuelling systemic inflammation that worsens cardiac function.

Cachexia and malnutrition: CHF promotes muscle wasting (cardiac cachexia) partly through inflammatory mechanisms. Gut dysfunction compounds this through impaired nutrient absorption.¹⁵

Breaking this cycle through nutritional support becomes paramount in CHF management. Strategies that support gut barrier function, promote beneficial microbiome composition, and provide highly bioavailable nutrients can help interrupt the gut-heart failure cycle and support better outcomes.

Hypertension and the Gut Microbiome

While hypertension (high blood pressure) is less commonly diagnosed in dogs than in humans, it remains an important cardiovascular concern, particularly secondary to kidney disease, endocrine disorders, or primary cardiac conditions. The gut microbiome influences blood pressure through several mechanisms relevant to canine cardiovascular health.^10,12

SCFA-mediated vasodilation: Short-chain fatty acids produced by beneficial bacteria interact with receptors in blood vessel walls, generally promoting vasodilation and healthy blood pressure. Reduced SCFA production from dysbiosis may contribute to vascular dysfunction.

Renin-angiotensin system modulation: Gut-derived metabolites influence the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. SCFAs particularly affect renal renin release and vascular angiotensin receptor expression.

Autonomic regulation: Gut-brain-heart communication through vagal pathways influences autonomic tone, affecting heart rate and vascular resistance.

Inflammatory influences: Chronic low-grade inflammation from gut dysbiosis promotes endothelial dysfunction and vascular stiffness, contributing to elevated blood pressure.

Supporting gut health may complement blood pressure management in dogs with or at risk for hypertension. Prebiotic fibres that promote SCFA production and anti-inflammatory nutritional strategies offer potential benefits for vascular health alongside direct cardiovascular support.

Nutritional Modulation of the Gut-Heart Axis

Understanding the gut-heart axis creates opportunities for targeted nutritional intervention. The following evidence-based strategies address both gut health and cardiovascular function, offering a comprehensive approach to supporting dogs with or at risk for heart disease.¹⁶

Prebiotics for Cardiovascular Health

Prebiotics are non-digestible food components that selectively promote the growth of beneficial gut bacteria. By supporting a healthy microbiome, prebiotics indirectly benefit cardiovascular health through increased SCFA production and reduced harmful metabolites.

Key prebiotic compounds for gut-heart support:

Fructooligosaccharides (FOS): Selectively feed Bifidobacteria and Lactobacillus species, promoting SCFA production and improving gut barrier function. FOS supplementation has been shown to reduce systemic inflammation markers in various species.

Mannan-oligosaccharides (MOS): Derived from yeast cell walls, MOS bind to pathogenic bacteria, preventing gut colonisation, while supporting beneficial bacterial populations and immune function.

Inulin: A soluble fibre fermented to butyrate by gut bacteria. Butyrate supports colonocyte health and gut barrier integrity while exerting anti-inflammatory effects systemically.

Beta-glucans: Derived from oats, barley, or yeast, beta-glucans provide fermentable substrate for beneficial bacteria while also directly modulating immune function and cholesterol metabolism.

Probiotics and Postbiotics

While direct evidence for probiotics for cardiovascular health (and canine heart disease) is still emerging, the established gut-heart axis mechanisms suggest potential benefits from microbiome modulation.

Probiotic considerations:

• Lactobacillus species: Produce lactic acid that inhibits pathogenic bacteria and may influence TMAO production pathways
• Bifidobacterium species: Excellent SCFA producers that support gut barrier function and anti-inflammatory signalling
• Bacillus velezensis (Calsporin®): A spore-forming probiotic with excellent gastrointestinal survival and documented safety and efficacy in dogs

Postbiotics: Postbiotics are bioactive compounds produced by probiotic metabolism or derived from inactivated probiotic cells. They offer advantages over live probiotics including greater stability, no risk of bacterial translocation in compromised patients, and consistent dosing. Products like TruPet® (and heat-inactivated Lactobacillus helveticus HA-122, Lactobacillus fermentum and Lactobacillus delbrueckii) provide immune-modulating and gut-supportive benefits without live bacteria concerns.

Omega-3 Fatty Acids

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), represent perhaps the most extensively studied nutritional intervention for canine cardiovascular disease, with benefits documented across multiple mechanisms.^8,18

Cardiovascular benefits of omega-3s:

Anti-arrhythmic effects: EPA and DHA stabilise cardiac cell membranes, reducing the risk of dangerous arrhythmias. A study in Boxer dogs with arrhythmogenic right ventricular cardiomyopathy found that fish oil supplementation significantly reduced ventricular arrhythmias.¹⁴

Anti-inflammatory action: Omega-3s serve as precursors to anti-inflammatory eicosanoids (resolvins and protectins) that counter the chronic inflammation driving cardiovascular disease progression.⁸

Anti-cachexia benefits: In dogs with heart failure, omega-3 supplementation has been shown to reduce muscle wasting and improve body condition, addressing the cachexia that worsens prognosis.¹⁵

Endothelial support: Omega-3s improve endothelial function, supporting healthy blood vessel dilation and reducing vascular resistance.

Triglyceride reduction: EPA and DHA lower plasma triglycerides, supporting overall cardiovascular metabolic health.

Dosing recommendations: For cardiovascular support, current evidence suggests 40-100 mg combined EPA+DHA per kilogram body weight daily.⁸ Higher doses toward the upper range may be appropriate for dogs with established heart disease, while lower maintenance doses support prevention. Algal sources like DHAgold® provide sustainable, contaminant-free DHA without the heavy metal concerns of fish oil.

Taurine and L-Carnitine

These amino acids play fundamental roles in cardiac muscle function, and their deficiency can directly cause cardiomyopathy.¹⁷

Taurine: This sulphur-containing amino acid is essential for cardiac muscle contractility, calcium handling, and osmoregulation. Dogs can synthesise taurine from methionine and cysteine, but certain conditions can lead to deficiency. These include specific dietary patterns, genetic factors, and gut dysfunction. Supplementation has shown remarkable efficacy in reversing taurine-deficient DCM.⁶’⁹

L-Carnitine: Essential for transporting long-chain fatty acids into mitochondria for energy production, L-carnitine is particularly important for cardiac muscle, which relies heavily on fatty acid oxidation. Deficiency impairs cardiac energy metabolism, while supplementation supports efficient ATP production in cardiomyocytes.¹⁷

The gut microbiome influences both nutrients, bacteria can metabolise taurine and carnitine, potentially reducing availability. Conversely, carnitine serves as a TMAO precursor, creating a nuanced picture. Plant-based diets naturally provide less carnitine while supplying adequate methionine and cysteine for taurine synthesis, potentially optimising both taurine status and TMAO production.^4,13

Coenzyme Q10

Note: While permissible in the USA COQ10 is yet to gain approved feed status for companion animals in the UK or EU

Coenzyme Q10 (CoQ10 or ubiquinone) is a vitamin-like compound essential for mitochondrial ATP production and serving as a powerful antioxidant. The heart, with its enormous energy demands, has particularly high CoQ10 requirements.

CoQ10 in cardiac health:

• Supports electron transport chain function for ATP synthesis
• Provides antioxidant protection against oxidative stress in cardiac tissues
• May improve cardiac function markers in dogs with heart disease
• Levels decline with age and in heart failure, suggesting supplementation benefit

While canine-specific CoQ10 research is limited, human studies consistently demonstrate benefits in heart failure, and the fundamental biochemistry applies across species. The ubiquinol form offers superior bioavailability compared to ubiquinone.

Anti-Inflammatory Botanicals

Plant-derived compounds can modulate the inflammatory pathways that link gut and heart health, offering gentle but effective support.

Key botanical compounds:

Curcumin: The active compound in turmeric inhibits NF-κB inflammatory signalling, reduces oxidative stress, and may improve endothelial function. Enhanced bioavailability formulations are essential for therapeutic effect.

Boswellia serrata: Contains boswellic acids that inhibit 5-lipoxygenase, reducing pro-inflammatory leukotriene production. Supports cardiovascular health through anti-inflammatory and antioxidant mechanisms.

Ginger (Zingiber officinale): Gingerols and shogaols provide anti-inflammatory and antioxidant benefits while supporting digestive function and gut health.

Hawthorn (Crataegus): Traditional cardiovascular botanical with research supporting mild positive inotropic effects, antioxidant activity, and blood pressure support. Often used in integrative heart disease management.

Antioxidants for Cardiac Protection

Oxidative stress plays a central role in cardiovascular disease progression. Both gut-derived inflammation and cardiac dysfunction generate reactive oxygen species that damage cellular components. A comprehensive antioxidant strategy supports both gut and heart health.

Key antioxidants:

Vitamin E: The primary fat-soluble antioxidant protecting cell membranes. Natural forms (RRR-alpha-tocopherol) offer superior bioactivity compared to synthetic dl-alpha-tocopherol.

Vitamin C: Water-soluble antioxidant that regenerates vitamin E and supports collagen synthesis important for blood vessel integrity. Dogs synthesise vitamin C but may benefit from supplementation during illness or stress.

Selenium: Essential cofactor for glutathione peroxidase, a key antioxidant enzyme protecting cardiac tissues. Supports thyroid function, which influences cardiovascular health.

Polyphenols: Plant compounds including flavonoids, anthocyanins, and phenolic acids provide antioxidant and anti-inflammatory benefits while also serving as prebiotics for beneficial gut bacteria.

Dietary Strategies for Cardiovascular Health

Beyond individual nutrients, overall dietary patterns influence gut-heart axis health. Evidence-based dietary strategies for cardiovascular support include:

Adequate protein quality, not excess quantity: High-quality, highly digestible protein supports cardiac muscle maintenance without overwhelming the gut with undigested material that feeds harmful bacteria or generates excessive TMAO precursors.

Fibre-rich formulations: Dietary fibre from diverse sources feeds SCFA-producing bacteria, supports gut barrier function, and may help reduce TMAO production by modifying microbiome composition.

Plant-based considerations: Research suggests plant-based diets may lower circulating TMAO precursors.⁴ Complete, balanced plant-based diets can support cardiovascular health while providing adequate taurine precursors (methionine, cysteine) and reducing substrate for TMAO production.

Moderate sodium for at-risk dogs: While severe sodium restriction is no longer recommended for most cardiac patients, moderate sodium levels support those with or at risk for fluid retention.

Highly digestible formulations: Especially important for dogs with CHF where gut function may be compromised. High digestibility ensures nutrient absorption while minimising undigested material reaching the colon.

Consistent, complete nutrition: Avoiding nutritional deficiencies that can directly impact cardiac function (taurine, carnitine, B vitamins) requires consistent feeding of balanced, complete diets rather than rotation or incomplete homemade formulations.

The 2023 Roberts/Swanson trial documented significantly lower serum cholesterol and triglycerides in dogs fed plant-based diets, alongside reduced faecal concentrations of the protein-fermentation by-products that act as precursors to cardiovascular-risk-associated uraemic toxins in humans. For the full peer-reviewed evidence on plant-based canine nutrition and cardiovascular-relevant outcomes, see the Bonza evidence review on plant-based dog food research.

Practical Implementation for Dog Owners

Translating gut-heart axis science into practical action requires a systematic approach. Consider these implementation strategies:

For all dogs (prevention):

• Feed a complete, balanced diet rich in prebiotic fibres
• Include omega-3 fatty acids at maintenance levels (40-50 mg EPA+DHA/kg daily)
• Support gut health with probiotics/postbiotics
• Ensure adequate taurine through diet or supplementation
• Maintain healthy weight to reduce cardiovascular strain

For predisposed breeds:

• Consider taurine supplementation, particularly for breeds with known deficiency risk
• Increase omega-3 fatty acid intake toward therapeutic levels
• Add L-carnitine support for breeds predisposed to cardiomyopathy
• Establish baseline cardiac screening with your veterinarian
• Focus intensively on gut health support

For dogs with heart disease:

• Work with your veterinarian to develop a comprehensive cardiac management plan
• Increase omega-3 fatty acids to therapeutic levels (80-100 mg EPA+DHA/kg daily)
• Ensure adequate taurine and L-carnitine intake
• Prioritise gut barrier support to reduce inflammatory burden
• Consider CoQ10 supplementation
• Feed highly digestible, nutrient-dense foods
• Monitor weight and body condition closely

For dogs with CHF:

• All of the above, plus intensive gut support to counter CHF-related gut dysfunction
• Consider multiple small meals for easier digestion
• Focus on caloric density to maintain weight despite reduced appetite
• Support with comprehensive antioxidant protection

Supporting Your Dog’s Gut-Heart Axis: The Bonza Approach

Bonza’s “One Gut. Whole Dog.” philosophy recognises that cardiovascular health is inseparable from the gut microbiome that regulates TMAO metabolism, SCFA production, and the systemic inflammation that determines cardiac risk. The gut-heart axis is one of the eight gut-organ axes underpinning Bonza’s formulation framework, informing both Superfoods & Ancient Grains and the Bioactive Bites supplement range. The daily food provides foundational gut-heart axis support through Calsporin®, TruPet™ postbiotic, prebiotic chicory, yeast-derived MOS and beta-glucans, DHAgold® algae-derived omega-3, and the PhytoPlus® botanical blend, working together through the Biotics Triad to maintain the microbiome balance and gut barrier integrity that cardioprotective SCFA signalling depends on. The plant-based formulation of Superfoods & Ancient Grains also provides a naturally lower dietary load of choline and betaine precursors associated with elevated TMAO production.

For dogs requiring targeted gut-heart axis support, Biotics Bioactive Bites is formulated to address the gut foundation of cardiovascular health, combining the complete Biotics Triad at therapeutic concentrations, TruPet™ postbiotic (285mg), Calsporin® (4.5 × 10⁴ CFU), and Lactobacillus helveticus (2.7 × 10⁹ CFU), alongside L-glutamine and zinc glycinate for gut barrier repair, clinoptilolite for endotoxin binding to reduce LPS-driven cardiac inflammation, and a concentrated anti-inflammatory botanical network of turmeric, boswellia, and ginger. Used together with Superfoods & Ancient Grains, Biotics addresses the gut-heart axis at both ends simultaneously, from the microbial regulation of cardiovascular metabolites to the barrier integrity that determines systemic inflammatory burden on cardiac tissue.

Frequently Asked Questions – Gut-Heart Axis in Dogs

Conclusion

The gut-heart axis represents a paradigm shift in how we understand and support canine cardiovascular health. No longer can we view the heart in isolation, it exists in constant dialogue with the gut, influenced by microbial metabolites, immune signals, and inflammatory pathways that connect these distant but intimately related organ systems.

Research increasingly demonstrates that dogs with heart disease, whether MMVD, DCM, or CHF, show characteristic gut dysbiosis and altered metabolite profiles.^1,2 These changes both result from and contribute to cardiac dysfunction, creating cycles that nutritional intervention can help interrupt. The gut-heart axis offers leverage points at multiple levels: microbiome composition, barrier function, metabolite production, and inflammatory signalling.

For dog owners, this science translates into actionable strategies: supporting gut health through prebiotics, probiotics, and postbiotics; providing cardioprotective omega-3 fatty acids at appropriate levels; ensuring adequate taurine and L-carnitine for cardiac muscle function; and choosing dietary patterns that optimise metabolite profiles while meeting complete nutritional needs.

Whether your goal is prevention in healthy dogs, proactive support in predisposed breeds, or complementary management in dogs with established heart disease, nurturing the gut-heart axis deserves a central place in your approach. The trillions of microorganisms in your dog’s gut are not passive residents, they are active participants in cardiovascular health, and supporting them means supporting the heart that keeps your companion thriving.

Explore the Gut-Organ Axes

• The Gut-Oral Axis in Dogs – The Health Implications
• The Dog Gut Microbiome: Vital Key to Dog Health
• Canine Gut-Organ Axes: How Gut Health Shapes Skin, Joints, Brain, and More
• The Gut-Immune Axis in Dogs – How Gut Health Supports Immune Health
• The Gut-Brain Axis in Dogs: The Impact of Nutrition
• The Gut-Skin Axis in Dogs: Why Skin Problems Start in the Gut
• The Gut-Joint Axis in Dogs – Nutritional Impact on Mobility
• The Gut-Metabolic Axis in Dogs – Powerful Health Regulator
• The Gut-Liver Axis in Dogs – Supporting Vital Detoxification
• The Gut-Longevity Axis in Dogs: Key To Improved Healthspan

References

1. Seo J, Matthewman L, Xia D, Wilshaw J, Chang YM, Connolly DJ. The gut microbiome in dogs with congestive heart failure: a pilot study. Sci Rep. 2020;10(1):13777. doi: 10.1038/s41598-020-70826-0. PMID: 32792610. PMC: PMC7426839.
2. Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA. Gut dysbiosis and its associations with gut microbiota-derived metabolites in dogs with myxomatous mitral valve disease. mSystems. 2021;6(2):e00111-21. doi: 10.1128/mSystems.00111-21. PMID: 33879495. PMC: PMC8546968.
3. Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA. Metabolomics analysis reveals deranged energy metabolism and amino acid metabolic reprogramming in dogs with myxomatous mitral valve disease. J Am Heart Assoc. 2021;10(9):e018923. doi: 10.1161/JAHA.120.018923. PMID: 33890477. PMC: PMC8200728.
4. Cavanaugh SM, Cavanaugh RP, Streeter R, Vieira AB, Gilbert GE, Ketzis JK. Commercial extruded plant-based diet lowers circulating levels of trimethylamine N-oxide (TMAO) precursors in healthy dogs: a pilot study. Front Vet Sci. 2022;9:936092. doi: 10.3389/fvets.2022.936092. PMC: PMC9300970.
5. Karlin ET, Rush JE, Freeman LM. A pilot study investigating circulating trimethylamine N-oxide and its precursors in dogs with degenerative mitral valve disease with or without congestive heart failure. J Vet Intern Med. 2019;33(1):46-53. doi: 10.1111/jvim.15347. PMID: 30511765. PMC: PMC6335534.
6. Kaplan JL, Stern JA, Fascetti AJ, Larsen JA, Skolnik H, Peddle GD, Kienle RD, Waxman A, Cocchiaro M, Gunther-Harrington CT, Klose T, LaFauci K, Lefbom B, Machen Lamy M, Malakoff R, Nishimura S, Oldach M, Rosenthal S, Stauthammer C, O’Sullivan L, Visser LC, Williams R, Ontiveros E. Taurine deficiency and dilated cardiomyopathy in golden retrievers fed commercial diets. PLoS One. 2018;13(12):e0209112. doi: 10.1371/journal.pone.0209112. PMID: 30543707. PMC: PMC6292607.
7. Freeman LM, Stern JA, Fries R, Adin DB, Rush JE. Diet-associated dilated cardiomyopathy in dogs: what do we know? J Am Vet Med Assoc. 2018;253(11):1390-1394. doi: 10.2460/javma.253.11.1390. PMID: 30451613.
8. Freeman LM. Beneficial effects of omega-3 fatty acids in cardiovascular disease. J Small Anim Pract. 2010;51(9):462-470. doi: 10.1111/j.1748-5827.2010.00968.x. PMID: 20673293.
9. Kittleson MD, Keene B, Pion PD, Loyer CG. Results of the multicenter spaniel trial (MUST): taurine- and carnitine-responsive dilated cardiomyopathy in American cocker spaniels with decreased plasma taurine concentration. J Vet Intern Med. 1997;11(4):204-211. doi: 10.1111/j.1939-1676.1997.tb00092.x. PMID: 9298474.
10. Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019;16(3):137-154. doi: 10.1038/s41569-018-0108-7. PMID: 30410105. PMC: PMC6377322.
11. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WHW, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. doi: 10.1038/nature09922. PMID: 21475195. PMC: PMC3086762.
12. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127(4):553-570. doi: 10.1161/CIRCRESAHA.120.316242. PMID: 32762536. PMC: PMC7416843.
13. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WHW, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-585. doi: 10.1038/nm.3145. PMID: 23563705. PMC: PMC3650111.
14. Smith CE, Freeman LM, Rush JE, Cunningham SM, Biourge V. Omega-3 fatty acids in Boxer dogs with arrhythmogenic right ventricular cardiomyopathy. J Vet Intern Med. 2007;21(2):265-273. doi: 10.1111/j.1939-1676.2007.tb02959.x. PMID: 17427387.
15. Freeman LM, Rush JE, Kehayias JJ, Ross JN Jr, Meydani SN, Brown DJ, Dolnikowski GG, Marmor BN, White ME, Dinarello CA, Roubenoff R. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med. 1998;12(6):440-448. doi: 10.1111/j.1939-1676.1998.tb02148.x. PMID: 9857337.
16. Li Q. Metabolic reprogramming, gut dysbiosis, and nutrition intervention in canine heart disease. Front Vet Sci. 2022;9:791754. doi: 10.3389/fvets.2022.791754. PMID: 35242837. PMC: PMC8886228.
17. Sanderson SL. Taurine and carnitine in canine cardiomyopathy. Vet Clin North Am Small Anim Pract. 2006;36(6):1325-1343. doi: 10.1016/j.cvsm.2006.08.010. PMID: 17085238.
18. Bauer JE. The essential nature of dietary omega-3 fatty acids in dogs. J Am Vet Med Assoc. 2016;249(11):1267-1272. doi: 10.2460/javma.249.11.1267. PMID: 27875089.

Editorial Information

Field	Detail
Published	17 January 2026
Last Updated	May 2026 (editorial review and plant-based diet research inclusion)
Reviewed by	Veterinary Advisory Board
Next Review	April 2027
Author	Glendon Lloyd, Dip. Canine Nutrition (Dist.), Dip. Dog Nutrigenomics (Dist.), Founder, Bonza
Disclaimer	This article is for informational purposes only and does not constitute veterinary advice. Always consult a qualified veterinarian before making changes to your dog’s diet or supplement regimen.